First in Men Study: BIOMAG-I
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 116 participants.
Also called NCT04157153
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 116 participants
- Sponsor
- Registry
-
NCT04157153
-
- Other papers using this trial's data
- The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria, Belgium, Germany, Netherlands, Poland, Spain, Sweden, Switzerland
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04157153. Allocation not applicable; no masking; primary purpose treatment. Start 2020-04-27 (actual); primary completion 2022-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- First in Men Study: BIOMAG-I
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
- Lead sponsor
- Biotronik AG
Record details
- Record id
cardio:ct-nct04157153- Content hash
e0b393a8779e2b6d21279111441b0943640a74b1f719b213dd831626f9a94e2c